1. Home
  2. OTLK vs AREC Comparison

OTLK vs AREC Comparison

Compare OTLK & AREC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OTLK
  • AREC
  • Stock Information
  • Founded
  • OTLK 2010
  • AREC 2013
  • Country
  • OTLK United States
  • AREC United States
  • Employees
  • OTLK N/A
  • AREC N/A
  • Industry
  • OTLK Biotechnology: Biological Products (No Diagnostic Substances)
  • AREC Coal Mining
  • Sector
  • OTLK Health Care
  • AREC Energy
  • Exchange
  • OTLK Nasdaq
  • AREC Nasdaq
  • Market Cap
  • OTLK 56.3M
  • AREC 55.3M
  • IPO Year
  • OTLK 2016
  • AREC 2019
  • Fundamental
  • Price
  • OTLK $1.48
  • AREC $0.46
  • Analyst Decision
  • OTLK Strong Buy
  • AREC Strong Buy
  • Analyst Count
  • OTLK 5
  • AREC 3
  • Target Price
  • OTLK $10.20
  • AREC $4.33
  • AVG Volume (30 Days)
  • OTLK 467.0K
  • AREC 2.0M
  • Earning Date
  • OTLK 02-14-2025
  • AREC 03-27-2025
  • Dividend Yield
  • OTLK N/A
  • AREC N/A
  • EPS Growth
  • OTLK N/A
  • AREC N/A
  • EPS
  • OTLK N/A
  • AREC N/A
  • Revenue
  • OTLK N/A
  • AREC $399,962.00
  • Revenue This Year
  • OTLK N/A
  • AREC N/A
  • Revenue Next Year
  • OTLK $288.46
  • AREC $3,208.62
  • P/E Ratio
  • OTLK N/A
  • AREC N/A
  • Revenue Growth
  • OTLK N/A
  • AREC N/A
  • 52 Week Low
  • OTLK $0.87
  • AREC $0.41
  • 52 Week High
  • OTLK $12.85
  • AREC $1.78
  • Technical
  • Relative Strength Index (RSI)
  • OTLK 41.52
  • AREC 33.55
  • Support Level
  • OTLK $1.38
  • AREC $0.47
  • Resistance Level
  • OTLK $1.56
  • AREC $0.68
  • Average True Range (ATR)
  • OTLK 0.12
  • AREC 0.09
  • MACD
  • OTLK 0.02
  • AREC -0.01
  • Stochastic Oscillator
  • OTLK 59.26
  • AREC 2.40

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

About AREC American Resources Corporation

American Resources Corp is a next-generation, environmentally, and socially responsible supplier of high-quality raw materials to the new infrastructure market. The firm is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. The firm has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated. Its business model provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure and electrification markets.

Share on Social Networks: